109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
局部晚期头颈部鳞状细胞癌的诱导化疗免疫治疗后放疗
Authors Tian Y , Fan Z , Qin Y, Zhang M, Xiong Y , Ren XY, Wang X, Wu S
Received 14 May 2025
Accepted for publication 26 September 2025
Published 13 October 2025 Volume 2025:17 Pages 2365—2375
DOI https://doi.org/10.2147/CMAR.S540239
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Kattesh Katti
Yan Tian,1,* Zenan Fan,1,* Yong Qin,2 Min Zhang,3 Yan Xiong,4 Xue-Ying Ren,5 Xiaoyun Wang,1 Shikai Wu1
1Department of Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 2Department of Otolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 3Department of Radiation Oncology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China; 4Department of Pathology, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 5Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shikai Wu, Department of Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China, Tel +86-010-64007836, Email skywu4923@sina.com
Introduction: The majority of head and neck squamous cell carcinomas (HNSCC) are diagnosed at an advanced stage, often necessitating standard treatments such as surgery or concurrent chemoradiotherapy.
Methods: This was a real-world study conducted between January 2021 and October 2024. The study enrolled 42 previously untreated patients diagnosed with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients received induction chemotherapy (IC) with or without immunotherapy followed by radiotherapy at our hospital.
Results: The group receiving immunotherapy with IC (I+IC, N=26) demonstrated an 82.6% objective response rate (ORR) and a 92.3% disease control rate (DCR). In contrast, patients treated with IC (N=16) alone exhibited an ORR of 37.5% and a DCR of 93.8%. With a median follow-up of 28.9 months, the I+IC group showed a 100% 6-month progression-free survival (PFS) and an 88.5% 12-month PFS, with a 92.3% overall survival (OS) rate at 12 months.
Discussion: This real-world study suggests that the addition of immunotherapy to IC holds promise for improving treatment outcomes in locally advanced HNSCC. The findings underscore the need for further research involving a larger patient population to validate these preliminary results.
Keywords: locally advanced head and neck squamous cell carcinoma, chemoimmunotherapy, induction chemotherapy, checkpoint inhibitor, immunotherapy
1Department of Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 2Department of Otolaryngology Head and Neck Surgery, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 3Department of Radiation Oncology, Peking University People’s Hospital, Beijing, 100044, People’s Republic of China; 4Department of Pathology, Peking University First Hospital, Beijing, 100034, People’s Republic of China; 5Department of Radiation Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Shikai Wu, Department of Oncology, Peking University First Hospital, Beijing, 100034, People’s Republic of China, Tel +86-010-64007836, Email skywu4923@sina.com
Introduction: The majority of head and neck squamous cell carcinomas (HNSCC) are diagnosed at an advanced stage, often necessitating standard treatments such as surgery or concurrent chemoradiotherapy.
Methods: This was a real-world study conducted between January 2021 and October 2024. The study enrolled 42 previously untreated patients diagnosed with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Patients received induction chemotherapy (IC) with or without immunotherapy followed by radiotherapy at our hospital.
Results: The group receiving immunotherapy with IC (I+IC, N=26) demonstrated an 82.6% objective response rate (ORR) and a 92.3% disease control rate (DCR). In contrast, patients treated with IC (N=16) alone exhibited an ORR of 37.5% and a DCR of 93.8%. With a median follow-up of 28.9 months, the I+IC group showed a 100% 6-month progression-free survival (PFS) and an 88.5% 12-month PFS, with a 92.3% overall survival (OS) rate at 12 months.
Discussion: This real-world study suggests that the addition of immunotherapy to IC holds promise for improving treatment outcomes in locally advanced HNSCC. The findings underscore the need for further research involving a larger patient population to validate these preliminary results.
Keywords: locally advanced head and neck squamous cell carcinoma, chemoimmunotherapy, induction chemotherapy, checkpoint inhibitor, immunotherapy